Iovance Biotherapeutics Stock Gains After Raising FY Revenue Guidance on Demand for Melanoma Treatments

By Kelly CloonanShares of Iovance Biotherapeutics rose after the company boosted its full-year revenue forecast, citing strong demand for two melanoma treatments.The stock gained 20% to $13.17 in premarket trading on Tuesday. At Monday's market close, shares had more than quadrupled year to date.Io…